title: Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India.
abstract: OBJECTIVE
  IL28B gene polymorphisms have been associated with treatment-response (sustained virological response, SVR) in genotype 1 hepatitis C virus (HCV)-infected patients, but only with early phase of viral decline (rapid virological response, RVR) with genotype 3 HCV-infected patients. Association between IL28B variants and SVR in genotype 3 HCV- infected patients is unclear. Our study aimed to replicate the association of IL28Bsingle nucleotide polymorphism (SNP) rs8099917 with SVR and to validate its association with RVR in genotype 3 HCV-infected patients.
  
  
  METHODS
  72 patients receiving combination therapy (interferon-alpha and ribavirin) at different Indian centers were retrospectively recruited and their genotype atrs8099917 was determined. The association with RVR and SVR was tested taking in to account the variation in relevant covariates such as age, gender, baseline HCV RNA copy number and liver enzymes.
  
  
  RESULTS
  The minor allele frequency (MAF) in the pooled samples was 0.17 at rs8099917 (G allele). 68% had TT, 29% had GT and 3% had the GG genotype. SVR was achieved in 71% of patients. A significant association ofrs8099917 with both RVR (p = 0.026) and SVR (p = 0.016) was observed with none of the covariates showing any significant association. The relapse rate was high (20%) but no association of rs8099917 was observed with relapse (p = 0.420).
  
  
  CONCLUSIONS
  An IL28B SNP associates with both early phase of viral decline and sustained response in a cohort of genotype 3 HCV-infected patients from India.
authors.forename: Sreedhar
authors.initials: S
authors.lastname: Chinnaswamy
authors.forename: Kausik
authors.initials: K
authors.lastname: Das
authors.forename: Bijan B
authors.initials: BB
authors.lastname: Bairagya
authors.forename: Chandrika
authors.initials: C
authors.lastname: Bhattacharyya
authors.lastname: Shalimar
authors.forename: Ajay
authors.initials: A
authors.lastname: Duseja
authors.forename: Deepak
authors.initials: D
authors.lastname: Amarapurkar
authors.lastname: Rosangluaia
authors.forename: Sujit
authors.initials: S
authors.lastname: Chowdhury
authors.forename: Ashokanand
authors.initials: A
authors.lastname: Konar
authors.forename: Partha P
authors.initials: PP
authors.lastname: Majumder
authors.forename: Abhijit
authors.initials: A
authors.lastname: Chowdhury
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007194:India; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda